A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

Sponsor

Idorsia Pharmaceuticals Ltd. (Industry)

Overall Status

Completed

CT.gov ID

NCT04798209

Collaborator

(none)

Enrollment

Location

Arms

15.7

Actual Duration (Months)

4.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: ACT-777991 (SAD) Drug: ACT-777991 (MAD) Drug: Placebo (SAD) Drug: Placebo (MAD) Drug: 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability) Drug: Microtracer matching placebo (SAD - Absolute Bioavailability) Drug: 14C-ACT-777991 microtracer (MAD - ADME) Drug: Microtracer matching placebo (MAD - ADME)	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

70 participants

Allocation:

Randomized

Intervention Model:

Sequential Assignment

Intervention Model Description:

Single-center, double-blind, randomized, placebo-controlled Phase 1 studySingle-center, double-blind, randomized, placebo-controlled Phase 1 study

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Other

Official Title:

A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

Actual Study Start Date :

Jan 29, 2021

Actual Primary Completion Date :

Jan 26, 2022

Actual Study Completion Date :

May 21, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Part A (single ascending dose) Dose A1 Single dose A1 of ACT-777991.	Drug: ACT-777991 (SAD) ACT-777991 administered as hard capsules for oral use. Drug: Placebo (SAD) ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A2 Single dose A2 of ACT-777991.	Drug: ACT-777991 (SAD) ACT-777991 administered as hard capsules for oral use. Drug: Placebo (SAD) ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A3 Single dose A3 of ACT-777991.	Drug: ACT-777991 (SAD) ACT-777991 administered as hard capsules for oral use. Drug: Placebo (SAD) ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A4 Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.	Drug: ACT-777991 (SAD) ACT-777991 administered as hard capsules for oral use. Drug: Placebo (SAD) ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A5 Single dose A5 of ACT-777991.	Drug: ACT-777991 (SAD) ACT-777991 administered as hard capsules for oral use. Drug: Placebo (SAD) ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A6 Single dose A6 of ACT-777991.	Drug: ACT-777991 (SAD) ACT-777991 administered as hard capsules for oral use. Drug: Placebo (SAD) ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A7 Single dose A7 of ACT-777991.	Drug: ACT-777991 (SAD) ACT-777991 administered as hard capsules for oral use. Drug: Placebo (SAD) ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A8 Single dose A8 of ACT-777991.	Drug: ACT-777991 (SAD) ACT-777991 administered as hard capsules for oral use. Drug: Placebo (SAD) ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part B (multiple ascending dose) Dose B1 Multiple doses B1 of ACT-777991.	Drug: ACT-777991 (MAD) ACT-777991 administered as hard capsules for oral use, once daily. Drug: Placebo (MAD) Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part B (multiple ascending dose) Dose B2 Multiple doses B2 of ACT-777991.	Drug: ACT-777991 (MAD) ACT-777991 administered as hard capsules for oral use, once daily. Drug: Placebo (MAD) Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part B (multiple ascending dose) Dose B3 Multiple doses B3 of ACT-777991.	Drug: ACT-777991 (MAD) ACT-777991 administered as hard capsules for oral use, once daily. Drug: Placebo (MAD) Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part B (multiple ascending dose) Dose B4 Multiple doses B4 of ACT-777991.	Drug: ACT-777991 (MAD) ACT-777991 administered as hard capsules for oral use, once daily. Drug: Placebo (MAD) Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part B (multiple ascending dose) Dose B5 Multiple doses B5 of ACT-777991.	Drug: ACT-777991 (MAD) ACT-777991 administered as hard capsules for oral use, once daily. Drug: Placebo (MAD) Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part A (single ascending dose) Absolute Bioavailability Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.	Drug: 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability) Single dose of 14C-ACT-777991 microtracer, administered intravenously. Drug: Microtracer matching placebo (SAD - Absolute Bioavailability) Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
Experimental: Part B (multiple ascending dose) ADME Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.	Drug: 14C-ACT-777991 microtracer (MAD - ADME) Single dose of 14C-ACT-777991 microtracer, oral solution.. Drug: Microtracer matching placebo (MAD - ADME) Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.

Outcome Measures

Primary Outcome Measures

Incidence of treatment-emergent adverse events. [From first dose on Day 1 to Day 4 after the last dose was administered]

Secondary Outcome Measures

All cohorts: Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of ACT-777991 [Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered]
All cohorts: Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf) of ACT-777991 [Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered]
All cohorts: Maximum plasma concentration (Cmax) of ACT-777991 [Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered]
All cohorts: Time to reach Cmax (tmax) of ACT-777991 [Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered]
All cohorts: Terminal half-life (t1/2) of ACT-777991 [Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered]
Part A (SAD): Absolute bioavailability of ACT-777991 [Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered]
Part B (MAD): Excretion of radioactivity in urine and feces [Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration)]
Part B (MAD): AUC during a dosing interval (AUCτ) following the first and the last dose of ACT-777991. [Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered]
Part A (SAD): Food effect evaluation only: AUC0-inf of ACT-777991 under fed conditions [Blood samples will be collected at predefined time points from Day 1 to Day 4.]
Part A (SAD): Food effect evaluation only: Cmax of ACT-777991 under fed conditions [Blood samples will be collected at predefined time points from Day 1 to Day 4.]
Part A (SAD): Food effect evaluation only: tmax of ACT-777991 under fed conditions [Blood samples will be collected at predefined time points from Day 1 to Day 4.]
Part A (SAD): Food effect evaluation only: t1/2 of ACT 777991 under fed conditions [Blood samples will be collected at predefined time points from Day 1 to Day 4.]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

General Inclusion Criteria:

Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.
Healthy male (Part A and B) and female subjects (Part B) aged between 18 and 55 years (inclusive) at Screening.
Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.
Male subjects with a partner who might become pregnant must either be vasectomized or agree to practice adequate contraception from admission to the study site until 3 months after dosing, or the partner must consistently and correctly use a highly effective method of contraception.

Inclusion Criteria for Part B:

Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use a highly effective method of contraception with a failure rate of less than 1% per year, be sexually inactive, or have a vasectomized partner.
Women of non-childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.

General Exclusion Criteria:

Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
History or clinical evidence of any disease and/or existence of any surgical or medical condition, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment.

Exclusion Criteria for the absorption,distribution, metabolism and excretion (ADME) evaluation:

Radiation exposure, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 milli sievert (mSv) in the last 12 months or 10 mSv in the last 5 years. Occupationally exposed workers, as defined in the relevant Ionising Radiation Regulations, must not participate in the study.
Participation in any study involving administration of any Carbon-14 (14C) radiolabeled compound within the 12 months prior to Screening.

Exclusion Criteria for Part B:

Pregnant or lactating women.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	QPS Netherlands B.V.	Groningen		Netherlands	9713 GZ

Sponsors and Collaborators

Idorsia Pharmaceuticals Ltd.

Investigators

Study Director: Clinical Trials, Idorsia Pharmaceuticals Ltd.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Idorsia Pharmaceuticals Ltd.

ClinicalTrials.gov Identifier:

NCT04798209

Other Study ID Numbers:

ID-089-101
2020-004464-26

First Posted:

Mar 15, 2021

Last Update Posted:

Jun 21, 2022

Last Verified:

Jun 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Study Results

No Results Posted as of Jun 21, 2022